- The next frontier in oligonucleotide synthesis is the direct synthesis of gene-length sequences. - Ansa synthesized a 1005 base long oligonucleotide with industry-leading accuracy. - Ansa will be ...

DNA synthesis is vital to several processes in biopharmaceutical innovation, including the development of gene therapies, CRISPR gene editing, antisense oligonucleotides and RNA therapies. The need ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Ansa Biotechnologies, Inc., a pioneer of next-generation DNA synthesis, today announced the appointment of Jason T. Gammack as its new chief executive officer.

There’s an old saying about a dollar waiting on a dime. In other words, a monumental endeavor may become stuck at some point if a key preliminary element remains unavailable. The saying could be ...

Last year, during the Global Synthetic Biology (SynBioBeta) conference, Ansa Biotechnologies’ CEO Jason Gammack introduced attendees to the company’s first product—600 bp synthetic DNA constructs.

Johnson and Alistar competed as finalists in CU Boulder’s 2025 Lab Venture Challenge where their technology generated much interest from industry leaders. Access to DNA is crucial in many branches of ...

DNA is the raw material of modern medicine yet is the only part of drug development not accessible at the lab bench. DNA synthesis, the first step in most biological workflows including gene synthesis ...